According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
A number of other equities analysts have also commented on the company. Leerink Swann reaffirmed a buy rating and issued a $54.00 price target on shares of DBV Technologies SA – in a report on Tuesday, August 23rd. JMP Securities initiated coverage on DBV Technologies SA – in a report on Monday. They issued an outperform rating and a $47.00 price target for the company. Finally, Jefferies Group reaffirmed a buy rating on shares of DBV Technologies SA – in a report on Wednesday, June 8th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $49.57.
DBV Technologies SA – (NASDAQ:DBVT) opened at 37.61 on Tuesday. The firm’s market cap is $1.73 billion. DBV Technologies SA – has a one year low of $22.55 and a one year high of $39.84. The firm has a 50-day moving average price of $35.17 and a 200-day moving average price of $33.27.
A number of large investors have recently bought and sold shares of DBVT. Royal Bank of Canada increased its stake in DBV Technologies SA – by 115.8% in the second quarter. Royal Bank of Canada now owns 4,100 shares of the company’s stock worth $133,000 after buying an additional 2,200 shares during the last quarter. BlackRock Institutional Trust Company N.A. purchased a new stake in DBV Technologies SA – during the second quarter worth $232,000. Geode Capital Management LLC increased its stake in DBV Technologies SA – by 15.9% in the first quarter. Geode Capital Management LLC now owns 9,237 shares of the company’s stock worth $300,000 after buying an additional 1,264 shares during the last quarter. DekaBank Deutsche Girozentrale increased its stake in DBV Technologies SA – by 12.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 11,100 shares of the company’s stock worth $360,000 after buying an additional 1,200 shares during the last quarter. Finally, Barclays PLC purchased a new stake in DBV Technologies SA – during the first quarter worth $400,000.
About DBV Technologies SA –
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.